

SPECTRUM PHARMACEUTICALS INC

Form 8-K/A

November 07, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K/A**

**(Amendment No. 1)**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 7, 2012**

**SPECTRUM PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**001-35006**

**93-0979187**

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 8-K/A

(State or Other Jurisdiction  
of Incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

**11500 S. Eastern Ave., Ste. 240, Henderson, NV**  
(Address of Principal Executive Offices)

**89052**  
(Zip Code)

**Registrant's telephone number, including area code: (702) 835-6300**

**Not Applicable**

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**EXPLANATORY NOTE**

On November 7, 2012 Spectrum Pharmaceuticals, Inc. (the Company) filed a Current Report earlier today on Form 8-K (the Initial 8-K) reporting the Company's results of operations for the quarter ended September 30, 2012. Pursuant to this Amendment No. 1 to the Initial 8-K, the Company hereby amends and supplements Item 9.01 of the Initial 8-K to file a corrected version of the Press Release.

The exhibit to the Initial 8-K inadvertently omitted certain financial tables. No other information, financial or otherwise, changed from the Initial 8-K. The Initial 8-K is only amended to the extent specifically provided herein and shall not otherwise be deemed amended or superseded in any other respect.

Filed as Exhibit 99.1 to this Amendment No. 1 is the Press Release as re-issued by the Company.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated November 7, 2012 as re-issued.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2012

**SPECTRUM PHARMACEUTICALS, INC.**

By: /s/ Brett L. Scott  
Brett L. Scott  
Senior Vice President and Acting Chief

Financial Officer

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press Release dated November 7, 2012 as re-issued.